The researchers analyzed data from 9,544 mpox cases among men between the ages of 18 and 49 that were reported during July 31 through Oct. 1 from 43 U.S. jurisdictions. There was not a significant variation of efficacy between whether the vaccine was delivered intradermally — when a fifth of a dose is administered in between layers of skin — or subcutaneously, but to “optimize strength of protection,” eligible people should receive two doses, the researchers wrote.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.